SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

August 04, 2011 07:00 ET

Radient Pharmaceuticals Enters Distribution Agreement With Uni Pharma for Onko-Sure Sales in Taiwan

TUSTIN, CA--(Marketwire - Aug 4, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has entered into an exclusive distribution agreement with Taiwan-based Uni Pharma, Co. Ltd. Uni Pharma will import, market, and sell Onko-Sure® in the Taiwanese market.

Onko-Sure® is a simple, non-invasive cancer blood test which has received regulatory approval in Taiwan as a general cancer tumor marker. Onko-Sure® is also approved as a general cancer tumor marker in several other Asian markets, as well as the European Union. The US FDA has cleared Onko-Sure® to market for monitoring colorectal cancer during treatment and for post-treatment recurrence monitoring. Onko-Sure® has also received regulatory approval for sale in Canada for lung cancer detection, treatment and recurrence monitoring.

"Having already built some traction in the Taiwanese market for Onko-Sure®, we are pleased to enter into this agreement with a partner like Uni Pharma. They have built well-established distribution and sales channels into doctors' offices, labs, and hospitals," stated Radient's Chairman and CEO, Mr. Douglas MacLellan.

Uni Pharma's General Manager, Mr. Terry Lin added, "Onko-Sure® is exactly what we were looking for in a high-value cancer diagnostic backed by strong clinical data from different clinical trial sites throughout the world. Our sales team has already received training in the U.S. from Radient's science and marketing executives. We've hired a Product Manager for Onko-Sure® who will focus exclusively on the marketing and sale of Onko-Sure®. We are excited and look forward to a successful launch throughout Taiwan."

About Uni Pharma:
Founded in 1998, Uni Pharma was established by a group of professional managers with multi-national pharmaceutical company backgrounds and extensive experience in the pharmaceutical industry. Uni Pharma is dedicated to supplying the best products to patients and delivering the most value to its partners. Uni Pharma distributes pharmaceutical and medical device products in Taiwan for nine international firms from seven countries across the globe. For more information please visit http://www.uni-pharma.com/gyhyenglish.html.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radient's business metrics.

RPC's Business Metrics
Cash on hand: $1.1 million*
*Approximate amount as of August 02, 2011
Shares Outstanding: 198 million*
*Approximate number as of August 02, 2011 and there are 200 million shares fully authorized.
Outstanding Warrants & Options: 111 million*
*Approximate number as of August 02, 2011

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.